Compare LFMD & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFMD | CRBU |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | United States | United States |
| Employees | 384 | 97 |
| Industry | Medical/Nursing Services | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.7M | 192.4M |
| IPO Year | N/A | 2021 |
| Metric | LFMD | CRBU |
|---|---|---|
| Price | $4.76 | $1.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $9.14 | ★ $10.75 |
| AVG Volume (30 Days) | 1.3M | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.52 | $1.63 |
| Revenue Next Year | $18.73 | $10.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.60 | $0.77 |
| 52 Week High | $15.34 | $3.53 |
| Indicator | LFMD | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 56.22 | 47.04 |
| Support Level | $3.39 | $1.70 |
| Resistance Level | $4.93 | $2.04 |
| Average True Range (ATR) | 0.36 | 0.12 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 47.16 | 20.54 |
LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.